Biomode
Financiado
Diagnosing Pathogen Bacteria Earlier and More Accurately with Biomode s Probe4@...
Diagnosing Pathogen Bacteria Earlier and More Accurately with Biomode s Probe4@ Rapid Diagnostic Kits
Over 23 million people in the Europe get ill from unsafe food every year, resulting in 5,000 deaths. The majority of foodborne diseases are diarrheal diseases including an estimated 5 million cases of campylobacteriosis annually....
Over 23 million people in the Europe get ill from unsafe food every year, resulting in 5,000 deaths. The majority of foodborne diseases are diarrheal diseases including an estimated 5 million cases of campylobacteriosis annually.
We have developed the Biomode Probe4@ solutions based on PNA-FISH technology. The Probe4@ products are cost-efficient, rapid and accurate molecular diagnostic tests based on Peptide Nucleic Acid Fluorescence in situ Hybridization (PNA-FISH) technology for the identification of pathogens in food safety, environmental and clinical applications.
Biomode is an innovative company where the core activities are focused on R&D and the commercialization of rapid diagnostic kits based on Peptide Nucleic Acid FISH technology for microbial detection in food and clinical samples. The company focus is to develop and certify its products by internationally recognized organizations such as AOAC. Currently our products Probe4Cronobacter®, Probe4Monocytogenes® and Probe4Salmonella® have already obtained the certification mark by AOAC. In the healthcare market, our product Probe4Pylori® has recently obtained the CE mark.
The EFSA has estimated that the overall economic burden of human salmonellosis could be as high as €3 billion a year. By preventing Salmonella to even to get into the retail system, early routine tests are necessary. But those will only be integrated if they are cost effective and easy to use such as the Biomode kits.
Our objective is to leverage the diagnostic possibilities of PNA-FISH for all its applications in food safety, clinical and environmental fields, thereby expanding the current possibilities of molecular analysis. We are convinced that the fast, accurate, low-cost and user-friendly diagnostic of certain pathogens through Biomode’s Probe4@ will help decision makers act quickly, thereby saving lives, pain, mistakes and even preventing epidemics.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2018-06-11
Fecha Fin: 2018-12-31
Fecha Fin: 2018-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
BIOMODE 2 S.A.
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
707.90K€ |
Participante